Open Journal of Nephrology

Volume 2, Issue 3 (September 2012)

ISSN Print: 2164-2842   ISSN Online: 2164-2869

Google-based Impact Factor: 0.42  Citations  

Do We Have a Biocompatible Peritoneal Dialysis Fluid?

HTML  Download Download as PDF (Size: 248KB)  PP. 29-34  
DOI: 10.4236/ojneph.2012.23005    3,279 Downloads   5,287 Views  


Objective: Cardiovascular disease remains the leading cause of morbidity and mortality in patients on maintenance dialysis. Diabetes mellitus, dyslipidemia, hypertension, inflammation and hyperhomocyteinemia are major cardiovascular risk factors. Aim: to evaluate the effects of Icodextrin and amino acid peritoneal dialysis fluid (AAPDF) on these major cardiovascular risk factors looking for a more biocompatible PDF formula. Methods: 24 adult stable peritoneal dialysis patients were included in the study. 12 patients received 2L Icodextrin and other 12 patients received 2L AAPDF in their dialysis prescription for 8 weeks. Results: Icodextrin decreased fasting plasma glucose (p < 0.001), LDL-C (p = 0.03), SBP (p < 0.01), DBP (p < 0.05) and plasma homocysteine (p = 0.002), and increased HDL-C (p = 0.009), CRP (p = 0.035) and fibrinogen (p = 0.009). AAPDF did not affect fasting plasma glucose, LDL-C, HDL-C, CRP and fibrinogen but increased serum albumin (p = 0.03), SBP (p < 0.01), DBP (p < 0.05) and PHcy (p = 0.03). Conclusions: A biocompatible PDF should provide not only adequate dialysis and ultrafiltration but should also improve nutritional and metabolic status, blood pressure control and reduce inflammation and plasma homocyteine.

Cite this paper

S. Hassan, B. Kristal, K. Khazim, F. Hassan, D. Hassan and K. Hassan, "Do We Have a Biocompatible Peritoneal Dialysis Fluid?," Open Journal of Nephrology, Vol. 2 No. 3, 2012, pp. 29-34. doi: 10.4236/ojneph.2012.23005.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.